Evidence map›Paper›PMID 40573382›Full record

ArticleViruses2025

Antiviral Intervention of COVID-19: Linkage of Disease Severity with Genetic Markers FGB (rs1800790), NOS3 (rs2070744) and TMPRSS2 (rs12329760).

Maksym Sokolenko, Larysa Sydorchuk, Alina Sokolenko, Ruslan Sydorchuk, Iryna Kamyshna, Andriy Sydorchuk, Ludmila Sokolenko, Oleksandr Sokolenko, Valentyn Oksenych, Oleksandr Kamyshnyi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Maksym SokolenkoDepartment of Infectious Diseases and Epidemiology, Bukovinian State Medical University, 58012 Chernivtsi, Ukraine.ORCID 0000-0002-7150-7146
Larysa SydorchukDepartment of Family Medicine, Bukovinian State Medical University, 58012 Chernivtsi, Ukraine.ORCID 0000-0001-9279-9531
Alina SokolenkoDepartment of Family Medicine, Bukovinian State Medical University, 58012 Chernivtsi, Ukraine.
Ruslan SydorchukDepartment of Surgery No 2, Bukovinian State Medical University, 58012 Chernivtsi, Ukraine.ORCID 0000-0002-3603-3432
Iryna KamyshnaDepartment of Medical Rehabilitation, I. Horbachevsky Ternopil National Medical University, 46001 Ternopil, Ukraine.ORCID 0000-0002-4483-1856
Andriy SydorchukDonauklinik, 89231 Neu Ulm, Germany.ORCID 0009-0001-6729-5603
Ludmila SokolenkoDepartment of Medical and Biological Fundamentals of Physical Culture, Pavlo Tychyna Uman State Pedagogical University, 20300 Uman, Ukraine.
Oleksandr SokolenkoDepartment of Infectious Diseases, Bukovinian State Medical University, 58012 Chernivtsi, Ukraine.
Valentyn OksenychBroegelmann Research Laboratory, Department of Clinical Science, University of Bergen, 5020 Bergen, Norway.ORCID 0000-0002-5088-3791
Oleksandr KamyshnyiDepartment of Microbiology, Virology, and Immunology, I. Horbachevsky Ternopil National Medical University, 46001 Ternopil, Ukraine.ORCID 0000-0003-3141-4436

Funding

RECOOP 36
6 · The paper itself

Abstract

The purpose of this study was to investigate polymorphic variants of the genes FGB (rs1800790), NOS3 (rs2070744) and TMPRSS2 (rs12329760) in patients with SARS-CoV-2 and to determine their role in the COVID-19 severity course against the background of antiviral therapy. Real-time polymerase chain reaction (RT-PCR) was used to genotype the polymorphism of the selected genes. GS-5734 (remdesivir) was prescribed as the basic antiviral drug. Binary logistic regression confirmed a low probability of COVID-19 developing in carriers of the A-allele of the FGB gene. The highest probability of moderate and severe COVID-19 clinical forms developing was found in G-allele carriers (especially the GG genotype) of the FGB gene (rs1800790) and the T-allele of the TMPRSS2 gene (rs12329760). Antiviral drug GS-5734 (remdesivir) administration with anti-inflammatory therapy reduces the TMPRSS2 blood level in moderate COVID-19, IL-6 in severe COVID-19 course, and fibrinogen A- and D-dimers in both groups. The proposed treatment does not significantly affect the concentration of endothelin-1, but a decrease in procalcitonin associated with additional antibacterial use was observed, especially in severe COVID-19.

Indexed as

Antiviral AgentsCOVID-19COVID-19 Drug TreatmentNitric Oxide Synthase Type IIISerine EndopeptidasesAdultAgedFemaleGenetic MarkersGenotypeHumansMaleMiddle AgedPolymorphism, Single NucleotideSARS-CoV-2Severity of Illness IndexAntiviral AgentsGenetic MarkersNitric Oxide Synthase Type IIINOS3 protein, humanSerine EndopeptidasesTMPRSS2 protein, humanantiviral treatmentCOVID-19FGB (rs1800790)genesNOS3 (rs2070744)polymorphismTMPRSS2 (rs12329760)

Identifiers

PMID40573382
PMCPMC12197352

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.